Oestrogen/NN
receptor/NN
(/(
ER/NN
)/)
analysis/NN
in/IN
B-cell/NN
chronic/JJ
lymphocytic/JJ
leukemia/NN
:/:
correlation/NN
of/IN
biochemical/JJ
and/CC
immunocytochemical/JJ
methods/NNS
./.

Oestrogen/NN
receptors/NNS
(/(
ER/NN
)/)
are/VBP
present/JJ
in/IN
neoplastic/JJ
lymphoid/JJ
cells/NNS
and/CC
have/VBP
been/VBN
considered/VBN
a/DT
physiological/JJ
marker/NN
of/IN
growth/NN
rate/NN
or/CC
differentiation/NN
./.
=====
Tamoxifen/NN
,/,
an/DT
oestrogen/NN
antagonist/NN
,/,
has/VBZ
been/VBN
given/VBN
in/IN
some/DT
patients/NNS
with/IN
CLL/NN
and/CC
Hodgkin/NN
's/POS
disease/NN
,/,
with/IN
dramatic/JJ
response/NN
in/IN
single/JJ
cases/NNS
./.
=====
Until/IN
now/NN
,/,
ER/NN
status/NN
has/VBZ
been/VBN
assessed/VBN
using/VBG
a/DT
steroid/NN
binding/NN
assay/NN
(/(
SBA/NN
)/)
which/WDT
has/VBZ
many/JJ
inherent/JJ
problems/NNS
./.
=====
Recently/RB
,/,
the/DT
development/NN
of/IN
monoclonal/JJ
antibodies/NNS
directed/VBN
against/IN
ER/NN
has/VBZ
been/VBN
applied/VBN
to/TO
the/DT
study/NN
of/IN
breast/NN
carcinomas/NNS
and/CC
results/NNS
obtained/VBN
show/VBP
good/JJ
correlation/NN
with/IN
the/DT
quantitative/JJ
SBA/NN
./.
=====
We/PRP
studied/VBD
49/CD
cases/NNS
of/IN
B-cell/NN
chronic/JJ
lymphocytic/JJ
leukemia/NN
(/(
CLL/NN
)/)
using/VBG
immunostaining/NN
of/IN
cytospin/NN
preparations/NNS
./.
=====
In/IN
30/CD
of/IN
these/DT
cases/NNS
ER/NN
enzyme/NN
immunoassay/NN
(/(
ER-EIA/NN
)/)
was/VBD
also/RB
performed/VBN
./.
=====
Cultured/VBN
MCF-7/NN
cells/NNS
,/,
derived/VBN
from/IN
a/DT
pleural/JJ
effusion/NN
of/IN
a/DT
breast/NN
cancer/NN
patient/NN
,/,
known/VBN
to/TO
contain/VB
high/JJ
levels/NNS
of/IN
ER/NN
were/VBD
used/VBN
as/IN
a/DT
positive/JJ
control/NN
(/(
40-48/CD
%/NN
ER/NN
positive/JJ
cells/NNS
by/IN
immunocytochemistry/NN
;/:
200/CD
fmol/mg/NN
protein/NN
by/IN
EIA/NN
)/)
./.
=====
All/DT
of/IN
the/DT
CLL/NN
cases/NNS
except/IN
two/CD
(/(
96/CD
%/NN
)/)
were/VBD
negative/JJ
for/IN
ER/NN
(/(
less/JJR
than/IN
1/CD
%/NN
staining/NN
;/:
less/JJR
than/IN
4/CD
fmol/mg/NN
protein/NN
)/)
./.
=====
The/DT
two/CD
positive/JJ
cases/NNS
expressed/VBD
granular/JJ
ER/NN
staining/NN
over/IN
the/DT
nucleus/NN
(/(
9.2/CD
and/CC
12.1/CD
%/NN
positive/JJ
cells/NNS
)/)
and/CC
were/VBD
positive/JJ
by/IN
EIA/NN
and/CC
SBA/NN
./.
=====
It/PRP
is/VBZ
concluded/VBN
that/IN
(/(
i/LS
)/)
patients/NNS
with/IN
CLL/NN
rarely/RB
express/VBP
ER/NN
and/CC
(/(
ii/LS
)/)
immunocytochemical/JJ
staining/NN
of/IN
cytospin/NN
preparations/NNS
is/VBZ
a/DT
valid/JJ
technique/NN
for/IN
the/DT
measurement/NN
of/IN
ER/NN
./.
=====
It/PRP
is/VBZ
of/IN
interest/NN
that/IN
one/CD
of/IN
the/DT
positive/JJ
cases/NNS
was/VBD
diagnosed/VBN
as/IN
CLL/NNP
with/IN
Richter/NN
's/POS
transformation/NN
confirming/VBG
earlier/JJR
findings/NNS
./.